Add like
Add dislike
Add to saved papers

Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore.

PURPOSE: To determine prognostic factors of Vogt-Koyanagi-Harada disease (VKH).

DESIGN: Retrospective noninterventional.

METHODS: Chart review of VKH patients of Singapore National Eye Centre for age at onset (age), gender, race, presenting visual acuity (VA) and VA at one month after starting treatment, severity of inflammation, treatment regime, and hearing loss. Outcome measures were: VA, persistent inflammation, cataracts, glaucoma, macular lesions, chorioretinal degeneration, and vitiligo at three years after onset.

RESULTS: There were 134 eyes of 67 patients. Majority were Chinese (n = 53, 79.1%) and female (n = 40, 59.7%). Median duration of follow-up was 9.1 years (range, 3.0 to 53.6 years). Median age was 42.3 years (range, 5.4 to 70.9 years). Main prognostic factors were VA at one month, age, and treatment regime. Good VA at one month was associated with greater likelihood of good VA at three years (odds ratio [OR], 43.9; P = .02), less persistent inflammation (OR, 0.5; P = .006), cataract (OR, 0.10; P = .01), and chorioretinal degeneration (OR, 0.2; P = .04). Older age was associated with higher likelihood of cataract (OR, 1.1; P = .02), chorioretinal degeneration (OR, 1.1; P = .03), and vitiligo (OR, 1.1; P = .004). Early treatment with high-dose systemic corticosteroids resulted in less persistent inflammation (OR, 0.2; P = .04). Late high corticosteroid treatment was associated with greater risk of cataract (OR, 9.6; P = .03).

CONCLUSION: Good VA at one month, younger age at onset, and early treatment with high-dose corticosteroids were associated with better outcomes.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app